EP
NGNE icon

Eversept Partners’s Neurogene NGNE Stock Holding History

Eversept Partners’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-3,686
Closed -$174K – 63
2019
Q2 		$174K Hold
3,686
– – 0.05% 62
2019
Q1 		$199K Hold
3,686
– – 0.06% 50
2018
Q4 		$159K Buy
+3,686
New +$180K 0.09% 52
2018
Q2 		– Sell
-1,599
Closed -$450K – 75
2018
Q1 		$450K Buy
1,599
+599
+60% +$165K 0.21% 51
2017
Q4 		$235K Buy
+1,000
New +$234K 0.14% 45

Other funds holding NGNE

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Eversept Partners's NGNE Position: Q3 2019 in Review

Eversept Partners sold out of Neurogene (NGNE) in Q3 2019, closing a stake of 3,686 shares — an estimated $174K sold.

Eversept Partners first reported a position in NGNE in Q4 2017 and held it in 5 quarters. The position peaked at $450K in Q1 2018. 36 funds tracked by Wall St. Rank hold NGNE as of Q3 2019.

  • Eversept Partners reported no remaining Neurogene position as of Q3 2019 after selling out during the quarter.
  • Eversept Partners sold 3,686 Neurogene shares in Q3 2019, an estimated $174K.
  • Eversept Partners first reported a position in Neurogene in Q4 2017 and held it in 5 quarters.
  • Eversept Partners's Neurogene position peaked at $450K in Q1 2018.
  • 36 funds tracked by Wall St. Rank held Neurogene as of Q3 2019.

Based on Eversept Partners's 13F filing for Q3 2019, filed 13 Nov 2019.